EGFR and cancer: Interestingly, in the study by Voduc and colleagues which used IHC to determine subtype, those cancers that were triple-negative and negative for the expression of EGFR and CK5/6 (non-basal triple-negatives), had a lower incidence of locoregional relapse when compared to the basal-like subtype [46].